Dexbrompheniramine and Phenylephrine Syrup and Viberzi
Determining the interaction of Dexbrompheniramine and Phenylephrine Syrup and Viberzi and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using eluxadoline together with dexbrompheniramine may increase the risk and/or severity of constipation and other gastrointestinal complications. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should stop taking eluxadoline and contact your doctor if you develop constipation that lasts more than 4 days. Always seek advice from a health care professional before taking any over-the-counter medications for diarrhea. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect. In placebo-controlled studies, constipation occurred in 7% and 8% of patients receiving eluxadoline 75 mg twice daily and 100 mg twice daily, respectively. Approximately 50% of constipation events occurred within the first 2 weeks of treatment, while the majority occurred within the first 3 months. The rates of constipation were similar between eluxadoline and placebo beyond the first 3 months of therapy.
MANAGEMENT: Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.
- "Product Information. Viberzi (eluxadoline)." Actavis Pharma, Inc., Parsippany, NJ.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: dexbrompheniramine / phenylephrine
Brand name: Ala Hist PE, Ala-Hist PE
Synonyms: Dexbrompheniramine and phenylephrine, Dexbrompheniramine and Phenylephrine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dexbrompheniramine and Phenylephrine Syrup-Vibra-Tabs
- Dexbrompheniramine and Phenylephrine Syrup-Vibramycin
- Dexbrompheniramine and Phenylephrine Syrup-Vibramycin (Doxycycline Suspension)
- Dexbrompheniramine and Phenylephrine Syrup-Vibramycin (Doxycycline Syrup)
- Dexbrompheniramine and Phenylephrine Syrup-Vibramycin (Doxycycline Tablets and Capsules)
- Dexbrompheniramine and Phenylephrine Syrup-Vibramycin Calcium
- Viberzi-Dexbrompheniramine and Phenylephrine Tablets
- Viberzi-Dexbrompheniramine and pseudoephedrine
- Viberzi-Dexbrompheniramine and Pseudoephedrine Solution
- Viberzi-Dexbrompheniramine and Pseudoephedrine Sustained-Release Tablets
- Viberzi-Dexbrompheniramine and Pseudoephedrine Tablets
- Viberzi-Dexbrompheniramine Tablets